Incyte Corp (NASDAQ:INCY)

During the Trading Day
87.91 -0.04 / -0.05%
As of 4:00pm ET
Day’s Change
During After-Hours   Switch to standard view »
88.50 +0.59 / +0.67%
 
Volume: 36.9K
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$15.1B

Company Description

Incyte Corp. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs. The company's product, Jakafi (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers. Incyte was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Contact Information

Incyte Corp.
Experimental Station
Wilmington Delaware 19880
P:(302) 498-6700
Investor Relations:
(302) 498-6944

Employees

Shareholders

Mutual fund holders64.61%
Other institutional35.11%
Individual stakeholders12.58%

Top Executives

Hervé HoppenotPresident, Chief Executive Officer & Director
David W. GryskaChief Financial Officer & Executive Vice President
Reid M. HuberChief Scientific Officer & Executive VP
Richard S. LevyEVP, Chief Drug Development & Medical Officer
Eric H. SiegelSecretary, Executive VP & General Counsel

To view my watchlist

Not a member yet?

Sign up now for a free account